Frontiers in Cardiovascular Medicine | |
Epigenetic Control of Mitochondrial Function in the Vasculature | |
Samuele Ambrosini1  Sarah Costantino1  Shafeeq A. Mohammed1  Francesco Paneni3  Thomas Lüscher4  | |
[1] Center for Molecular Cardiology, University of Zürich, Zurich, Switzerland;Department of Cardiology, University Heart Center, University Hospital Zurich, Zurich, Switzerland;Department of Research and Education, University Hospital Zurich, Zurich, Switzerland;Research, Education and Development, Royal Brompton and Harefield Hospital Trust and Imperial College, London, United Kingdom; | |
关键词: epigenetics; mitochondria; vascular disease; oxidative stress; endothelial function; | |
DOI : 10.3389/fcvm.2020.00028 | |
来源: DOAJ |
【 摘 要 】
The molecular signatures of epigenetic regulation and chromatin architecture are emerging as pivotal regulators of mitochondrial function. Recent studies unveiled a complex intersection among environmental factors, epigenetic signals, and mitochondrial metabolism, ultimately leading to alterations of vascular phenotype and increased cardiovascular risk. Changing environmental conditions over the lifetime induce covalent and post-translational chemical modification of the chromatin template which sensitize the genome to establish new transcriptional programs and, hence, diverse functional states. On the other hand, metabolic alterations occurring in mitochondria affect the availability of substrates for chromatin-modifying enzymes, thus leading to maladaptive epigenetic signatures altering chromatin accessibility and gene transcription. Indeed, several components of the epigenetic machinery require intermediates of cellular metabolism (ATP, AcCoA, NADH, α-ketoglutarate) for enzymatic function. In the present review, we describe the emerging role of epigenetic modifications as fine tuners of gene transcription in mitochondrial dysfunction and vascular disease. Specifically, the following aspects are described in detail: (i) mitochondria and vascular function, (ii) mitochondrial ROS, (iii) epigenetic regulation of mitochondrial function; (iv) the role of mitochondrial metabolites as key effectors for chromatin-modifying enzymes; (v) epigenetic therapies. Understanding epigenetic routes may pave the way for new approaches to develop personalized therapies to prevent mitochondrial insufficiency and its complications.
【 授权许可】
Unknown